{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["antibiotics", "macrolides", "neuroprotection", "neuroregeneration", "spinal cord injury", "\u03b2-lactams"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33464681", "DateCompleted": {"Year": "2021", "Month": "10", "Day": "08"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "10", "Day": "14"}], "Language": ["eng"], "ELocationID": ["10.1111/fcp.12605"], "Journal": {"ISSN": "1472-8206", "JournalIssue": {"Volume": "35", "Issue": "2", "PubDate": {"Year": "2021", "Month": "Apr"}}, "Title": "Fundamental & clinical pharmacology", "ISOAbbreviation": "Fundam Clin Pharmacol"}, "ArticleTitle": "Antibiotics with therapeutic effects on spinal cord injury: a review.", "Pagination": {"StartPage": "277", "EndPage": "304", "MedlinePgn": "277-304"}, "Abstract": {"AbstractText": ["Accumulating evidence indicates that a considerable number of antibiotics exert anti-inflammatory and neuroprotective effects in different central and peripheral nervous system diseases including spinal cord injury (SCI). Both clinical and preclinical studies on SCI have found therapeutic effects of antibiotics from different families on SCI. These include macrolides, minocycline, \u03b2-lactams, and dapsone, all of which have been found to improve SCI sequels and complications. These antibiotics may target similar signaling pathways such as reducing inflammatory microglial activity, promoting autophagy, inhibiting neuronal apoptosis, and modulating the SCI-related mitochondrial dysfunction. In this review paper, we will discuss the mechanisms underlying therapeutic effects of these antibiotics on SCI, which not only could supply vital information for investigators but also guide clinicians to consider administering these antibiotics as part of a multimodal therapeutic approach for management of SCI and its complications."], "CopyrightInformation": "\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et de Th\u00e9rapeutique."}, "AuthorList": [{"Identifier": ["0000-0001-9099-7948"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran."}, {"Identifier": [], "Affiliation": "Experimental Medicine Research Center, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, 01655, USA."}], "LastName": "Afshari", "ForeName": "Khashayar", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran, P. O. Box: 19419-33111, Iran."}], "LastName": "Momeni Roudsari", "ForeName": "Nazanin", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran, P. O. Box: 19419-33111, Iran."}], "LastName": "Lashgari", "ForeName": "Naser-Aldin", "Initials": "NA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran."}, {"Identifier": [], "Affiliation": "Experimental Medicine Research Center, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, 01655, USA."}], "LastName": "Haddadi", "ForeName": "Nazgol-Sadat", "Initials": "NS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Experimental Medicine Research Center, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran."}], "LastName": "Haj-Mirzaian", "ForeName": "Arvin", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, 1419733141, Iran."}], "LastName": "Hassan Nejad", "ForeName": "Malihe", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Experimental Medicine Research Center, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran."}], "LastName": "Shafaroodi", "ForeName": "Hamed", "Initials": "H"}, {"Identifier": ["0000-0002-1384-9826"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurology, University of Massachusetts School of Medicine, Worcester, MA, 01655, USA."}], "LastName": "Ghasemi", "ForeName": "Mehdi", "Initials": "M"}, {"Identifier": ["0000-0002-8001-5565"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran."}, {"Identifier": [], "Affiliation": "Experimental Medicine Research Center, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran."}], "LastName": "Dehpour", "ForeName": "Ahmad Reza", "Initials": "AR"}, {"Identifier": ["0000-0001-9961-9097"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran, P. O. Box: 19419-33111, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, 31375-1369, Iran."}, {"Identifier": [], "Affiliation": "Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, 1419733151, Iran."}], "LastName": "Abdolghaffari", "ForeName": "Amir Hossein", "Initials": "AH"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Fundam Clin Pharmacol", "NlmUniqueID": "8710411", "ISSNLinking": "0767-3981"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Bacterial Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}], "MeshHeadingList": [{"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Anti-Bacterial Agents"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Spinal Cord"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Spinal Cord Injuries"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ahmad M., Zakaria A., Almutairi K.M. Effectiveness of minocycline and FK506 alone and in combination on enhanced behavioral and biochemical recovery from spinal cord injury in rats. Pharmacol. Biochem. Behav. (2016) 145 45-54."}, {"Citation": "Cardenas D.D., Hoffman J.M., Kirshblum S., McKinley W. Etiology and incidence of rehospitalization after traumatic spinal cord injury: a multicenter analysis. Arch. Phys. Med. Rehabil. (2004) 85 1757-1763."}, {"Citation": "Evans C.T., Smith B., Parada J.P., Kurichi J.E., Weaver F.M. Trends in antibiotic prescribing for acute respiratory infection in veterans with spinal cord injury and disorder. J. Antimicrob. Chemother. (2005) 55 1045-1049."}, {"Citation": "Evans C.T., Rogers T.J., Weaver F.M., Burns S.P. Providers' beliefs and behaviors regarding antibiotic prescribing and antibiotic resistance in persons with spinal cord injury or disorder. J. Spinal Cord Med. (2011) 34 16-21."}, {"Citation": "Ahuja C.S., Nori S., Tetreault L. et al. Traumatic spinal cord injury-repair and regeneration. Neurosurgery (2017) 80 S9-S22."}, {"Citation": "Wang Z., Nong J., Shultz R.B. et al. Local delivery of minocycline from metal ion-assisted self-assembled complexes promotes neuroprotection and functional recovery after spinal cord injury. Biomaterials (2017) 112 62-71."}, {"Citation": "Beattie M.S., Hermann G.E., Rogers R.C., Bresnahan J.C. Cell death in models of spinal cord injury. Prog. Brain Res. (2002) 37-47."}, {"Citation": "Dumont R.J., Verma S., Okonkwo D.O. et al. Acute spinal cord injury, part II: contemporary pharmacotherapy. Clin. Neuropharmacol. (2001) 24 265-279."}, {"Citation": "Estes M.L., McAllister A.K. Alterations in immune cells and mediators in the brain: it's not always neuroinflammation!. Brain Pathol. (2014) 24 623-630."}, {"Citation": "Chen G., Zhou Z., Sha W. et al. A novel CX3CR1 inhibitor AZD8797 facilitates early recovery of rat acute spinal cord injury by inhibiting inflammation and apoptosis. Int. J. Mol. Med. (2020) 45 1373-1384."}, {"Citation": "Gensel J.C., Kopper T.J., Zhang B., Orr M.B., Bailey W.M. Predictive screening of M1 and M2 macrophages reveals the immunomodulatory effectiveness of post spinal cord injury azithromycin treatment. Sci. Rep. (2017) 7 40144."}, {"Citation": "Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. (2009) 29 13435-13444."}, {"Citation": "Rostami A., Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J. Neurol. Sci. (2013) 333 76-87."}, {"Citation": "Hall E.D., Wang J.A., Bosken J.M., Singh I.N. Lipid peroxidation in brain or spinal cord mitochondria after injury. J. Bioenerg. Biomembr. (2016) 48 169-174."}, {"Citation": "R\u00edos C., Orozco-Suarez S., Salgado-Ceballos H. et al. Anti-apoptotic effects of dapsone after spinal cord injury in rats. Neurochem. Res. (2015) 40 1243-1251."}, {"Citation": "Poniatowski \u0141.A., Wojdasiewicz P., Krawczyk M. et al. Analysis of the role of CX3CL1 (Fractalkine) and its receptor CX3CR1 in traumatic brain and spinal cord injury: insight into recent advances in actions of neurochemokine agents. Mol. Neurobiol. (2017) 54 2167-2188."}, {"Citation": "Kwiecien J.M., Dabrowski W., D\u0105browska-Bouta B. et al. Prolonged inflammation leads to ongoing damage after spinal cord injury. PLoS One (2020) 15 e0226584."}, {"Citation": "Liu X.-Y., Guo J.-W., Kou J.-Q., Sun Y.-L., Zheng X.-J. Repair mechanism of astrocytes and non-astrocytes in spinal cord injury. World J. Clin. Cases. (2020) 8 854."}, {"Citation": "Livshits A., Rappaport Z.H., Livshits V., Gepstein R. Surgical treatment of painful spasticity after spinal cord injury. Spinal Cord. (2002) 40 161-166."}, {"Citation": "Spai\u0107 M., Markovi\u0107 N., Tadi\u0107 R. Microsurgical DREZotomy for pain of spinal cord and Cauda equina injury origin: clinical characteristics of pain and implications for surgery in a series of 26 patients. Acta Neurochir (Wien). (2002) 144 453-462."}, {"Citation": "Olby N. Current concepts in the management of acute spinal cord injury. J. Vet. Intern. Med. (1999) 13 399-407."}, {"Citation": "Zhou P., Guan J., Xu P. et al. Cell therapeutic strategies for spinal cord injury. Adv. Wound Care (New Rochelle). (2019) 8 585-605."}, {"Citation": "Jorge A., Taylor T., Agarwal N., Hamilton D.K. Current agents and related therapeutic targets for inflammation after acute traumatic spinal cord injury. World Neurosurg. (2019) 132 138-147."}, {"Citation": "Baptiste D.C., Fehlings M.G. Pharmacological approaches to repair the injured spinal cord. J. Neurotrauma (2006) 23 318-334."}, {"Citation": "Baptiste D.C., Fehlings M.G. Update on the treatment of spinal cord injury. Prog. Brain Res. (2007) 161 217-233."}, {"Citation": "Badhiwala J.H., Ahuja C.S., Fehlings M.G. Time is spine: a review of translational advances in spinal cord injury. J Neurosurg Spine. (2018) 30 1-18."}, {"Citation": "Silva N.A., Sousa N., Reis R.L., Salgado A.J. From basics to clinical: a comprehensive review on spinal cord injury. Prog. Neurobiol. (2014) 114 25-57."}, {"Citation": "Haller J., Bice M., Lawrence B. Mediating the secondary effects of spinal cord injury through optimization of key physiologic parameters. J. Am. Acad. Orthop. Surg. (2016) 24 160-171."}, {"Citation": "Farsi L., Keshavarz M., Afshari K., Javidan A.N. Intravenous granulocyte colony-stimulating factor administration can attenuate neuropathic pain following spinal cord injury in male rats. Acta Medica Iranica. (2018) 56 226-233."}, {"Citation": "Plemel J.R., Yong V.W., Stirling D.P. Immune modulatory therapies for spinal cord injury-past, present and future. Exp. Neurol. (2014) 258 91-104."}, {"Citation": "Ulndreaj A., Badner A., Fehlings M.G. Promising neuroprotective strategies for traumatic spinal cord injury with a focus on the differential effects among anatomical levels of injury. F1000Research (2017) 6 1907."}, {"Citation": "Papa S., Rossi F., Ferrari R. et al. Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury. ACS Nano. (2013) 7 9881-9895."}, {"Citation": "Lee S.M., Yune T.Y., Kim S.J. et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J. Neurotrauma (2003) 20 1017-1027."}, {"Citation": "Shultz R.B., Zhong Y. Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury. Neural Regen. Res. (2017) 12 702-713."}, {"Citation": "Diaz-Ruiz A., Salgado-Ceballos H., Montes S. et al. Delayed administration of dapsone protects from tissue damage and improves recovery after spinal cord injury. J. Neurosci. Res. (2011) 89 373-380."}, {"Citation": "Festoff B.W., Ameenuddin S., Arnold P.M., Wong A., Santacruz K.S., Citron B.A. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J. Neurochem. (2006) 97 1314-1326."}, {"Citation": "Zhang B., Bailey W.M., Kopper T.J., Orr M.B., Feola D.J., Gensel J.C. Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury. J. Neuroinflammation (2015) 12 1-13."}, {"Citation": "Wong S.S.H. Nutrition management of spinal cord injured patients: an investigation of resources and interventions in UK spinal cord injuries centres. University of London, London, 2019."}, {"Citation": "Roberts T.T., Leonard G.R., Cepela D.J. Classifications In Brief: American Spinal Injury Association (ASIA) Impairment Scale. Clinical orthopaedics and related research (2017) 475(5) 1499-1504."}, {"Citation": "van Den Hauwe L., Sundgren P.C., Flanders A.E. Spinal Trauma and Spinal Cord Injury (SCI). Spinal trauma and Spinal Cord Injury (SCI). Diseases of the brain, head and neck, spine 2020-2023. Springer, Cham, Switzerland. 2020, pp. 231-40."}, {"Citation": "Kirshblum S.C., Burns S.P., Biering-Sorensen F. et al. International standards for neurological classification of spinal cord injury (revised 2011). J. Spinal Cord Med. (2011) 34 535-546."}, {"Citation": "Papa S., Mauri E., Rossi F., Perale G., Veglianese P. Introduction to spinal cord injury as clinical pathology. Spinal Cord Injury (SCI) Repair Strategies. Elsevier, Amsterdam, The Netherlands. (2020), pp. 1-12."}, {"Citation": "Simard J.M., Gerzanich V. When replication teaches more than the original experiment-the saga of the unknown unknown. Exp. Neurol. (2012) 233 623-624."}, {"Citation": "Marquis A., Packer R.A., Borgens R.B., Duerstock B.S. Increase in oxidative stress biomarkers in dogs with ascending-descending myelomalacia following spinal cord injury. J. Neurol. Sci. (2015) 353 63-69."}, {"Citation": "Martineau J., Goulet J., Richard-Denis A., Mac-Thiong J.M. The relevance of MRI for predicting neurological recovery following cervical traumatic spinal cord injury. Spinal Cord (2019) 57 866-873."}, {"Citation": "Bondurant F.J., Cotler H. B., Kulkarni M. V., McARDLE C. B., Harris J. H. Acute spinal cord injury. Spine (1990) 15 161-168."}, {"Citation": "van Den Hauwe L., Sundgren P.C., Flanders A.E. Spinal Trauma and Spinal Cord Injury (SCI), in: Hodler J., Kubik-Huch R.A., von Schulthess G.K. (Eds), Diseases of the Brain, head and neck, spine 2020-2023: diagnostic imaging [Internet]. Springer, Cham, 2020, pp. 231-240."}, {"Citation": "Hodler J., Kubik-Huch R.A., von Schulthess G.K.Diseases of the brain, head and neck. Spine 2020-2023."}, {"Citation": "Bennett J.E., Dolin R., Blaser M.J. Mandell, douglas, and Bennett's principles and practice of infectious diseases: 2-volume set. Amsterdam, The Netherlands: Elsevier Health Sciences, 2014."}, {"Citation": "Zhang B., Kopper T.J., Liu X., Cui Z., Van Lanen S.G., Gensel J.C. Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity. CNS Neurosci. Ther. (2019) 25 591-600."}, {"Citation": "Inaba T., Katayama Y., Ueda M., Nito C. Neuroprotective effects of pretreatment with macrolide antibiotics on cerebral ischemia reperfusion injury. Neurol. Res. (2015) 37 514-524."}, {"Citation": "Amantea D., Certo M., Petrelli F., Bagetta G. Neuroprotective properties of a macrolide antibiotic in a mouse model of middle cerebral artery occlusion: characterization of the immunomodulatory effects and validation of the efficacy of intravenous administration. Assay Drug Dev. Technol. (2016) 14 298-307."}, {"Citation": "Barks J.D., Liu Y., Wang L., Pai M.P., Silverstein F.S. Repurposing azithromycin for neonatal neuroprotection. Pediatr. Res. (2019) 86 444-451."}, {"Citation": "Murphy B.S., Sundareshan V., Cory T.J., Hayes D. Jr, Anstead M.I., Feola D.J. Azithromycin alters macrophage phenotype. J. Antimicrob. Chemother. (2008) 61 554-560."}, {"Citation": "Haydar D., Cory T.J., Birket S.E. et al. Azithromycin polarizes macrophages to an M2 phenotype via inhibition of the STAT1 and NF-\u03baB signaling pathways. J. Immunol. (2019) 203 1021-1030."}, {"Citation": "Ahmed A., Patil A.A., Agrawal D.K. Immunobiology of spinal cord injuries and potential therapeutic approaches. Mol. Cell Biochem. (2018) 441 181-189."}, {"Citation": "Thompson C.D., Zurko J.C., Hanna B.F., Hellenbrand D.J., Hanna A. The therapeutic role of interleukin-10 after spinal cord injury. J. Neurotrauma. (2013) 30 1311-1324."}, {"Citation": "Kambayashi T., Jacob C.O., Strassmann G. IL-4 and IL-13 modulate IL-10 release in endotoxin-stimulated murine peritoneal mononuclear phagocytes. Cell. Immunol. (1996) 171 153-158."}, {"Citation": "Surh Y.-J., Chun K.-S., Cha H.-H. et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-\u03baB activation. Mut. Res. (2001) 480 243-268."}, {"Citation": "Lupher M.L. Jr, Gallatin W.M. Regulation of fibrosis by the immune system. Adv. Immunol. (2006) 89 245-288."}, {"Citation": "Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. (2002) 23 549-555."}, {"Citation": "Vran\u010di\u0107 M., Banjanac M., Nuji\u0107 K. et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br. J. Pharmacol. (2012) 165 1348-1360."}, {"Citation": "Banjanac M., Kos V.M., Nuji\u0107 K. et al. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A. 1 cells. Pharmacol. Res. (2012) 66 357-362."}, {"Citation": "Gao X., Ray R., Xiao Y., Ishida K., Ray P. Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Pulm. Pharmacol. Ther. (2010) 23 97-106."}, {"Citation": "Meyer M., Huaux F., Gavilanes X. et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. (2009) 41 590-602."}, {"Citation": "Sugiyama K., Shirai R., Mukae H. et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin. Exp. Immunol. (2007) 147 540-546."}, {"Citation": "Yamauchi K., Shibata Y., Kimura T. et al. Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-\u03b3 stimulated macrophages. Int. J. Biol. Sci. (2009) 5 667."}, {"Citation": "Gensel J.C., Donahue R.R., Bailey W.M., Taylor B.K. Sexual dimorphism of pain control: analgesic effects of pioglitazone and azithromycin in chronic spinal cord injury. J Neurotrauma. (2019) 36 2372-2376."}, {"Citation": "Kopper T.J., McFarlane K.E., Bailey W.M., Orr M.B., Zhang B., Gensel J.C. Delayed azithromycin treatment improves recovery after mouse spinal cord injury. Front. Cell. Neurosci. (2019) 13 490."}, {"Citation": "Fiorillo M., T\u00f3th F., Sotgia F., Lisanti M.P. Doxycycline, azithromycin and vitamin C (DAV): a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). Aging (2019) 11 2202-2216."}, {"Citation": "Gorgey A.S., Witt O., O'Brien L. et al. Mitochondrial health and muscle plasticity after spinal cord injury. Eur. J. Appl. Physiol. (2019) 119 315-331."}, {"Citation": "Scholpa N.E., Schnellmann R.G. Mitochondrial-based therapeutics for the treatment of spinal cord injury: mitochondrial biogenesis as a potential pharmacological target. J. Pharmacol. Exp. Ther. (2017) 363 303-313."}, {"Citation": "Kullmann A.F., Truschel S.T., Wolf-Johnston A.S. et al. Acute spinal cord injury is associated with mitochondrial dysfunction in mouse urothelium. Neurourol. Urodyn. (2019) 38 1551-1559."}, {"Citation": "Kullmann F., Truschel S., McDonnell B. et al. Mitochondrial-targeted antioxidant therapy improves spinal cord injury associated urothelial dysfunction. Neurourol. Urodyn. (2018) 363(3) S207-S208."}, {"Citation": "Clanton L.J. Jr, Bender J. Refractory spinal cord injury induced gastroparesis: resolution with erythromycin lactobionate, a case report. J. Spinal Cord. Med. (1999) 22 236-238."}, {"Citation": "Koutsogiannidis C.P., Johnson E.O. Pharmacological neuroprotection in cardiac surgery: effectiveness of pharmacologic-preconditioning with erythromycin. Curr. Vasc. Pharmacol. (2018) 16 329-335."}, {"Citation": "Xu Z., Li Z. Experimental study on the role of apelin-13 in alleviating spinal cord ischemia reperfusion injury through suppressing autophagy. Drug Design Dev. Ther. (2020) 14 1571."}, {"Citation": "Katayama Y., Inaba T., Nito C., Ueda M. Neuroprotective effects of erythromycin on ischemic injury following permanent focal cerebral ischemia in rats. Neurol. Res. (2016) 38 275-284."}, {"Citation": "Preston D.A. Microbiological aspects of erythromycin. Pediatr. Infect. Dis. (1986) 5 120-123."}, {"Citation": "Thomas D., Wilkie D. Inhibition of mitochondrial synthesis in yeast by erythromycin: cytoplasmic and nuclear factors controlling resistance. Genet. Res. (1968) 11 33-41."}, {"Citation": "Doersen C.-J., Stanbridge E.J. Erythromycin inhibition of cell proliferation and in vitro mitochondrial protein synthesis in human HeLa cells is pH dependent. Biochim. Biophys. Acta (1982) 698 62-69."}, {"Citation": "Jiang C., Wang T., Xu Z.-J., Chao X., Duez P. Investigation on the mode of action of the traditional Chinese medical prescription-yiqihuoxue formula, an effective extravasation treatment for cerebral vascular microemboli in ApoE-/-mice. World J. Traditional Chinese Med. (2020) 6 112."}, {"Citation": "Wang J., Xu Y., Wan H., Hu J. Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress. Biochem. Biophys. Res. Comm. (2018) 497 241-247."}, {"Citation": "Zhu M., Li Y., Zhou Z. Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage. Biochem. Biophys. Res. Commun. (2017) 492 373-378."}, {"Citation": "Cairns D.M., Giordano J.E., Conte S., Levin M., Kaplan D.L. Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing. ACS Omega. (2018) 3 12392-12402."}, {"Citation": "Costa J.L., Diazgranados J.A. Ivermectin for spasticity in spinal-cord injury. Lancet (London, England). (1994) 343 739."}, {"Citation": "Illes P., Rubini P., Ulrich H., Zhao Y., Tang Y. Regulation of microglial functions by purinergic mechanisms in the healthy and diseased CNS. Cells (2020) 9 1108."}, {"Citation": "Tacrolimus. LiverTox: Clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012."}, {"Citation": "Cai J., Sun Y., Yin Z. et al. Analysis of FK506-mediated functional recovery and neuroprotection in a rat model of spinal cord injury indicates that EGF is modulated in astrocytes. Exp Ther Med. (2018) 16 501-510."}, {"Citation": "Liu G., Fan G., Guo G. et al. FK506 attenuates the inflammation in rat spinal cord injury by inhibiting the activation of NF-kappaB in microglia cells. Cell. Mol. Neurobiol. (2017) 37 843-855."}, {"Citation": "Madsen J.R., MacDonald P., Irwin N. et al. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp. Neurol. (1998) 154 673-683."}, {"Citation": "Saganova K., Galik J., Blasko J., Korimova A., Racekova E., Vanicky I. Immunosuppressant FK506: focusing on neuroprotective effects following brain and spinal cord injury. Life Sci. (2012) 91 77-82."}, {"Citation": "Yamazaki K., Kawabori M., Seki T. et al. FTY720 attenuates neuropathic pain after spinal cord injury by decreasing systemic and local inflammation in a rat spinal cord compression model. J. Neurotrauma (2020) 37 1720-1728."}, {"Citation": "Qian K., Xu T.-Y., Wang X. et al. Effects of neural stem cell transplantation on the motor function of rats with contusion spinal cord injuries: a meta-analysis. Neural Regen. Res. (2020) 15 748."}, {"Citation": "Paskal A.M., Paskal W., Pietruski P. et al. Neuroregenerative effects of polyethylene glycol and FK-506 in a rat model of sciatic nerve injury. J. Plastic Reconstr. Aesthet. Surg. (2020) 73 222-230."}, {"Citation": "Bavetta S., Hamlyn P.J., Burnstock G., Lieberman A.R., Anderson P.N. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp. Neurol. (1999) 158 382-393."}, {"Citation": "Akgun S., Tekeli A., Kurtkaya O. et al. Neuroprotective effects of FK-506, L-carnitine and azathioprine on spinal cord ischemia-reperfusion injury. Eur. J. Cardiothorac. Surg. (2004) 25 105-110."}, {"Citation": "Ahmad M., Alshehri A.S. Effects of Cyclosporin-A, Minocycline, and Tacrolimus (FK506) on Enhanced Behavioral and Biochemical Recovery from Spinal Cord Injury in Rats. Spinal Cord Injury Therapy. IntechOpen, London, UK, 2019."}, {"Citation": "Uzun T., Toptas O., Saylan A., Carver H., Turkoglu S.A. Evaluation and comparison of the effects of artesunate, dexamethasone, and tacrolimus on sciatic nerve regeneration. J. Oral Maxillofac. Surg. (2019) 77 1092.e1-e12."}, {"Citation": "Zuo K.J., Saffari T.M., Chan K., Shin A.Y., Borschel G.H. Systemic and local FK506 (Tacrolimus) and its application in peripheral nerve surgery. J. Hand Surg. (2020) 45 759-765."}, {"Citation": "Lopez-Vales R., Garcia-Alias G., Fores J. et al. FK 506 reduces tissue damage and prevents functional deficit after spinal cord injury in the rat. J. Neurosci. Res. (2005) 81 827-836."}, {"Citation": "Lang-Lazdunski L., Heurteaux C., Dupont H., Rouelle D., Widmann C., Mantz J. The effects of FK506 on neurologic and histopathologic outcome after transient spinal cord ischemia induced by aortic cross-clamping in rats. Anest. Analg. (2001) 92 1237-1244."}, {"Citation": "Sabra M., Alawieh A., Zaraket F.A. Intractome curation and analysis for stroke and spinal cord injury using semiautomatic annotations. Leveraging Biomedical and Healthcare Data. Elsevier, Academic Press, Cambridge, Massachusetts, USA, 2019, pp. 151-66. https://doi.org/10.1016/B978-0-12-809556-0.00011-3"}, {"Citation": "Nottingham S., Knapp P., Springer J. FK506 treatment inhibits caspase-3 activation and promotes oligodendroglial survival following traumatic spinal cord injury. Exp. Neurol. (2002) 177 242-251."}, {"Citation": "Hayashi Y., Shumsky J.S., Connors T. et al. Immunosuppression with either cyclosporine a or FK506 supports survival of transplanted fibroblasts and promotes growth of host axons into the transplant after spinal cord injury. J. Neurotrauma. (2005) 22 1267-1281."}, {"Citation": "Lopez-Vales R., Fores J., Navarro X., Verdu E. Olfactory ensheathing glia graft in combination with FK506 administration promote repair after spinal cord injury. Neurobiol. Dis. (2006) 24 443-454."}, {"Citation": "Voda J., Hama A., Sagen J. FK506 reduces the severity of cutaneous hypersensitivity in rats with a spinal cord contusion. Neurosci. Res. (2007) 58 95-99."}, {"Citation": "Aras M., Altas M., Dokuyucu R. et al. Protective effects of minocycline on experimental spinal cord injury in rats. Injury (2015) 46 1471-1474."}, {"Citation": "Sirolimus. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012."}, {"Citation": "Li X.G., Du J.H., Lu Y., Lin X.J. Neuroprotective effects of rapamycin on spinal cord injury in rats by increasing autophagy and Akt signaling. Neural Regen. Res. (2019) 14 721-727."}, {"Citation": "Li J., Kim S.G., Blenis J. Rapamycin: one drug, many effects. Cell Metab. (2014) 19 373-379."}, {"Citation": "Badve S.V., Pascoe E.M., Burke M. et al. Mammalian target of rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients. Clin. J. Am. Soc. Nephrol. (2016) 11 1845-1855."}, {"Citation": "Pan M., de Lezo J.S., Medina A. et al. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am. Heart J. (2004) 148 857-864."}, {"Citation": "Wang X., Li X., Huang B., Ma S. Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury. Transl. Neurosc. (2016) 7 50-55."}, {"Citation": "Nie J., Chen J., Yang J. et al. Inhibition of mammalian target of rapamycin complex 1 signaling by n-3 polyunsaturated fatty acids promotes locomotor recovery after spinal cord injury. Mol. Med. Rep. (2018) 17 5894-5902."}, {"Citation": "Zhou R., Kan S., Cai S., Sun R., Yuan H., Yu B. Scopoletin activates adenosine monophosphate-activated protein kinase/mammalian target of rapamycin signaling pathway and improves functional recovery after spinal cord injury in rats. Pharmacology (2020) 105 349-359."}, {"Citation": "Song Y., Xue H., Liu T.T., Liu J.M., Chen D. Rapamycin plays a neuroprotective effect after spinal cord injury via anti-inflammatory effects. J. Biochem. Mol. Toxicol. (2015) 29 29-34."}, {"Citation": "Lashgari N., Roudsari N., Momtaz S. et al. Targeting mammalian target of rapamycin: prospects for the treatment of inflammatory bowel diseases. Curr. Med. Chem. (2020) 27. https://doi.org/10.2174/0929867327666200504081503"}, {"Citation": "Sekiguchi A., Kanno H., Ozawa H., Yamaya S., Itoi E. Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. J. Neurotrauma. (2012) 29 946-956."}, {"Citation": "Chen H.C., Fong T.H., Hsu P.W., Chiu W.T. Multifaceted effects of rapamycin on functional recovery after spinal cord injury in rats through autophagy promotion, anti-inflammation, and neuroprotection. J. Surg. Res. (2013) 179 e203-e210."}, {"Citation": "Goldshmit Y., Kanner S., Zacs M. et al. Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury. Mol. Cell Neurosci. (2015) 68 82-91."}, {"Citation": "Kanno H., Ozawa H., Sekiguchi A. et al. The role of mTOR signaling pathway in spinal cord injury. Cell Cycle (Georgetown, Tex). (2012) 11 3175-3179."}, {"Citation": "Tateda S., Kanno H., Ozawa H. et al. Rapamycin suppresses microglial activation and reduces the development of neuropathic pain after spinal cord injury. J. Orthop. Res. (2017) 35 93-103."}, {"Citation": "Eldahan K.C., Cox D.H., Gollihue J.L., Patel S.P., Rabchevsky A.G. Rapamycin exacerbates cardiovascular dysfunction after complete high-thoracic spinal cord injury. J. Neurotrauma. (2018) 35 842-853."}, {"Citation": "Kjell J., Pernold K., Olson L., Abrams M.B. Oral erlotinib, but not rapamycin, causes modest acceleration of bladder and hindlimb recovery from spinal cord injury in rats. Spinal Cord. (2014) 52 186-190."}, {"Citation": "Gao K., Wang Y.S., Yuan Y.J. et al. Neuroprotective effect of rapamycin on spinal cord injury via activation of the Wnt/beta-catenin signaling pathway. Neural Regen. Res. (2015) 10 951-957."}, {"Citation": "Fang B., Li X.Q., Bao N.R. et al. Role of autophagy in the bimodal stage after spinal cord ischemia reperfusion injury in rats. Neuroscience (2016) 328 107-116."}, {"Citation": "Li Q., Gao S., Kang Z. et al. Rapamycin enhances mitophagy and attenuates apoptosis after spinal ischemia-reperfusion injury. Front. Neurosci. (2018) 12 865."}, {"Citation": "Rabchevsky A.G., Michael F.M., Patel S.P. Mitochondria focused neurotherapeutics for spinal cord injury. Exp. Neurol. (2020) 330 113332."}, {"Citation": "Li C., Yuan K., Schluesener H. Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis. Rev Neurosci. (2013) 24 553-562."}, {"Citation": "Orsucci D., Calsolaro V., Mancuso M., Siciliano G. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol. Disord. Drug Targets. (2009) 8 222-231."}, {"Citation": "Santa-Cecilia F.V., Leite C.A., Del-Bel E., Raisman-Vozari R. The neuroprotective effect of doxycycline on neurodegenerative diseases. Neurotox. Res. (2019) 35 981-986."}, {"Citation": "Domercq M., Matute C. Neuroprotection by tetracyclines. Trends Pharmacol. Sci. (2004) 25 609-612."}, {"Citation": "Kuhle J., Gaiottino J., Leppert D. et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J. Neurol. Neurosurg. Psychiatry. (2015) 86 273-279."}, {"Citation": "Casha S., Zygun D., McGowan M.D., Bains I., Yong V.W., Hurlbert R.J. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain (2012) 135 1224-1236."}, {"Citation": "Carnini A., Casha S., Yong V.W., Hurlbert R.J., Braun J.E. Reduction of PrPC in human cerebrospinal fluid after spinal cord injury. Prion. (2010) 4 80-86."}, {"Citation": "Minocycline. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2012."}, {"Citation": "Siddiqui A.M., Khazaei M., Fehlings M.G. Translating mechanisms of neuroprotection, regeneration, and repair to treatment of spinal cord injury. Prog. Brain Res. (2015) 218 15-54."}, {"Citation": "Nazemi Z., Nourbakhsh M.S., Kiani S. et al. Co-delivery of minocycline and paclitaxel from injectable hydrogel for treatment of spinal cord injury. J. Controlled Release (2020) 321 145-158."}, {"Citation": "Radad K., El Amir Y., Al-Emam A. et al. Minocycline protects against acrylamide-induced neurotoxicity and testicular damage in Sprague-Dawley rats. J. Toxicol. Pathol. (2020) 33 87-95."}, {"Citation": "Shah M., Peterson C., Yilmaz E., Halalmeh D.R., Moisi M. Current advancements in the management of spinal cord injury: A comprehensive review of literature. Surg. Neurol. Int. (2020) 475(5) 1499-1504."}, {"Citation": "Wells J.E., Hurlbert R.J., Fehlings M.G., Yong V.W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain (2003) 126 1628-1637."}, {"Citation": "Chen D., Zeng W., Fu Y., Gao M., Lv G. Bone marrow mesenchymal stem cells combined with minocycline improve spinal cord injury in a rat model. Int. J. Clin. Exp. Pathol. (2015) 8 11957."}, {"Citation": "Liu X., Su H., Chu T.H., Guo A., Wu W. Minocycline inhibited the pro-apoptotic effect of microglia on neural progenitor cells and protected their neuronal differentiation in vitro. Neurosci. Lett. (2013) 542 30-36."}, {"Citation": "Teng Y.D., Choi H., Onario R.C. et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl Acad. Sci. USA (2004) 101 3071-3076."}, {"Citation": "Afshari K., Dehdashtian A., Haddadi N.-S. et al. Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: Introduction of an alternative therapy. Spinal Cord. (2018) 56 1032."}, {"Citation": "Afshary K., Chamanara M., Talari B., Rezaei P., Nassireslami E. Therapeutic effects of minocycline pretreatment in the locomotor and sensory complications of spinal cord injury in an animal model. J. Mol. Neurosci. (2020) 70 1064-1072."}, {"Citation": "Ijaz S., Mohammed I., Gholaminejhad M., Mokhtari T., Akbari M., Hassanzadeh G. Modulating pro-inflammatory cytokines, tissue damage magnitude, and motor deficit in spinal cord injury with subventricular zone-derived extracellular vesicles. J. Mol. Neurosci. (2020) 70 458-466."}, {"Citation": "Colburn R., Rickman A., DeLeo J. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp. Neurol. (1999) 157 289-304."}, {"Citation": "Dunn J.S., Nagi S.S., Mahns D.A. Minocycline reduces experimental muscle hyperalgesia induced by repeated nerve growth factor injections in humans: A placebo-controlled double-blind drug-crossover study. Eur. J. Pain (2020) 24 1138-1150."}, {"Citation": "Krady J.K., Basu A., Allen C.M. et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes (2005) 54 1559-1565."}, {"Citation": "Hains B.C. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J. Neurosci. (2006) 26 4308-4317."}, {"Citation": "Bin S., Zhou N., Pan J., Pan F., Wu X.F., Zhou Z.H. Nano-carrier mediated co-delivery of methyl prednisolone and minocycline for improved post-traumatic spinal cord injury conditions in rats. Drug Dev. Ind. Pharm. (2017) 43 1033-1041."}, {"Citation": "Zhao P., Waxman S.G., Hains B.C. Extracellular signal-regulated kinase-regulated microglia-neuron signaling by prostaglandin E2 contributes to pain after spinal cord injury. J. Neurosci. (2007) 27 2357-2368."}, {"Citation": "Kerr B.J., Patterson P.H. Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse. Exp. Neurol. (2004) 188 391-407."}, {"Citation": "Chu L.-S., Fang S.-H., Zhou Y. et al. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats 1. Acta Pharmacol. Sin. (2007) 28 763-772."}, {"Citation": "Meng F.X., Hou J.M., Sun T.S. In vivo evaluation of microglia activation by intracranial iron overload in central pain after spinal cord injury. J. Orthop. Surg. Res. (2017) 12 75."}, {"Citation": "Lee C.G., Homer R.J., Zhu Z. et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor \u03b21. J. Exp. Med. (2001) 194 809-822."}, {"Citation": "Shinoda M., Fujita S., Sugawara S. et al. Suppression of superficial microglial activation by spinal cord stimulation attenuates neuropathic pain following sciatic nerve injury in rats. Int. J. Mol. Sci. (2020) 21 2390."}, {"Citation": "Garcia-Martinez E.M., Sanz-Blasco S., Karachitos A. et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem. Pharmacol. (2010) 79 239-250."}, {"Citation": "Rodr\u0131\u0301guez E., M\u00e9ndez-Armenta M., Villeda-Hern\u00e1ndez J. et al. Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology (1999) 139 111-118."}, {"Citation": "Lambs L., Brion M., Berthon G. Metal ion-tetracycline interactions in biological fluids. Part 3. Formation of mixed-metal ternary complexes of tetracycline, oxytetracycline, doxycycline and minocycline with calcium and magnesium, and their involvement in the bioavailability of these antibiotics in blood plasma. Agents Actions (1984) 14 743-750."}, {"Citation": "Chen-Roetling J., Chen L., Regan R.F. Minocycline attenuates iron neurotoxicity in cortical cell cultures. Biochem. Biophys. Res. Comm. (2009) 386 322-326."}, {"Citation": "Huang C.-L., Lee Y.-C., Yang Y.-C., Kuo T.-Y., Huang N.-K. Minocycline prevents paraquat-induced cell death through attenuating endoplasmic reticulum stress and mitochondrial dysfunction. Toxicol. Lett. (2012) 209 203-210."}, {"Citation": "Grenier D., Huot M.-P., Mayrand D. Iron-chelating activity of tetracyclines and its impact on the susceptibility of actinobacillus actinomycetemcomitansto these antibiotics. Antimicrob. Agents Chemother. (2000) 44 763-766."}, {"Citation": "Venkat A., Chaitanya P., Ravinder P., Shilendra D. Protective role of Minocycline through zinc chelation in LPS induced Alzheimer\u2019s model. JSRP (2013) 2 1-7."}, {"Citation": "Bauer G., Berens C., Projan S.J., Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. (2004) 53 592-599."}, {"Citation": "Shen Y., Kishimoto K., Linden D.J., Sapirstein A. Cytosolic phospholipase A2 alpha mediates electrophysiologic responses of hippocampal pyramidal neurons to neurotoxic NMDA treatment. Proc. Natl Acad. Sci. USA (2007) 104 6078-6083."}, {"Citation": "Zhao Z., Liu N., Huang J., Lu P.H., Xu X.M. Inhibition of cPLA2 activation by Ginkgo biloba extract protects spinal cord neurons from glutamate excitotoxicity and oxidative stress-induced cell death. J. Neurochem. (2011) 116 1057-1065."}, {"Citation": "Kriem B., Sponne I., Fifre A. et al. Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-\u03b2 peptide. FASEB J. (2005) 19 85-87."}, {"Citation": "Santamar\u00eda A., Ordaz-Moreno J., Rubio-Osornio M., Sol\u00eds-Hern\u00e1ndez F., R\u00edos C. Neuroprotective effect of dapsone against quinolinate-and kainate-induced striatal neurotoxicities in rats. Pharmacol. Toxicol. (1997) 81 271-275."}, {"Citation": "Yong V.W., Wells J., Giuliani F., Casha S., Power C., Metz L.M. The promise of minocycline in neurology. Lancet Neurol. (2004) 3 744-751."}, {"Citation": "Zang D.W., Cheema S.S. Leukemia inhibitory factor promotes recovery of locomotor function following spinal cord injury in the mouse. J. Neurotrauma (2003) 20 1215-1222."}, {"Citation": "Arvin K.L., Han B.H., Du Y., Lin S.Z., Paul S.M., Holtzman D.M. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol. (2002) 52 54-61."}, {"Citation": "Seukeran D.C., Eady E.A., Cunliffe W.J. Benefit-risk assessment of acne therapies. Lancet (1997) 349 1251-1252."}, {"Citation": "Cho D.C., Cheong J.H., Yang M.S., Hwang S.J., Kim J.M., Kim C.H. The effect of minocycline on motor neuron recovery and neuropathic pain in a rat model of spinal cord injury. J. Korean Neurosurg. Soc. (2011) 49 83."}, {"Citation": "Pinzon A., Marcillo A., Quintana A. et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res. (2008) 1243 146-151."}, {"Citation": "Teng Y.D., Choi H., Onario R.C., Zhu S., Desilets F.C., Lan S. et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proco. Natl Acad. Sci. USA. (2004) 101 3071-3076."}, {"Citation": "Webster K.A. Mitochondrial membrane permeabilization and cell death during myocardial infarction: roles of calcium and reactive oxygen species. Future Cardiol. (2012) 8 863-884."}, {"Citation": "Zhu S., Stavrovskaya I.G., Drozda M. et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417 74."}, {"Citation": "Stirling D.P., Koochesfahani K.M., Steeves J.D., Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist (2005) 11 308-322."}, {"Citation": "Cai J., Yang J., Jones D. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim. Biophys. Acta (1998) 1366 139-149."}, {"Citation": "Saiwai H., Ohkawa Y., Yamada H. et al. The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Am. J. Pathol. (2010) 176 2352-2366."}, {"Citation": "Chen M., Ona V.O., Li M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. (2000) 6 797."}, {"Citation": "Hermann G.E., Rogers R.C., Bresnahan J.C., Beattie M.S. Tumor necrosis factor-\u03b1 induces cFOS and strongly potentiates glutamate-mediated cell death in the rat spinal cord. Neurobiol. Dis. (2001) 8 590-599."}, {"Citation": "Baumgartner H.K., Gerasimenko J.V., Thorne C. et al. Calcium elevation in mitochondria is the main Ca2+ requirement for mitochondrial permeability transition pore (mPTP) opening. J. Biol. Chem. (2009) 284 20796-208803."}, {"Citation": "Dong X.-X., Wang Y., Qin Z.-H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. (2009) 30 379."}, {"Citation": "Lee J.H., Tigchelaar S., Liu J. et al. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury. Exp. Neurol. (2010) 225 219-230."}, {"Citation": "Karimi-Abdolrezaee S. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J. Neurosci. (2006) 26 3377-3389."}, {"Citation": "Stirling D.P. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. (2004) 24 2182-2190."}, {"Citation": "Pang T., Wang J., Benicky J., Saavedra J.M. Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition. Biochim. Biophys. Acta (2012) 1820 503-510."}, {"Citation": "Hahn J.N., Kaushik D.K., Mishra M.K., Wang J., Silva C., Yong V.W. Impact of minocycline on extracellular matrix metalloproteinase inducer, a factor implicated in multiple sclerosis immunopathogenesis. J. Immunol. (2016) 197 3850-3860."}, {"Citation": "Saganov\u00e1 K., Orend\u00e1\u010dov\u00e1 J., \u010c\u00ed\u017ekov\u00e1 D., Vanick\u00fd I. Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. Neurosci. Lett. (2008) 433 246-249."}, {"Citation": "Casha S., Zygun D., McGowan M.D., Bains I., Yong V.W., John Hurlbert R. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain (2012) 135 1224-1236."}, {"Citation": "Choi S.H., Lee D.Y., Chung E.S., Hong Y.B., Kim S.U., Jin B.K. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J. Neurochem. (2005) 95 1755-1765."}, {"Citation": "Sung C.S., Cherng C.H., Wen Z.H. et al. Minocycline and fluorocitrate suppress spinal nociceptive signaling in intrathecal IL-1\u03b2-induced thermal hyperalgesic rats. Glia (2012) 60 2004-2017."}, {"Citation": "Spencer N.G., Schilling T., Miralles F., Eder C. Mechanisms underlying interferon-\u03b3-induced priming of microglial reactive oxygen species production. PLoS One (2016) 11 e0162497."}, {"Citation": "Genovese T., Cuzzocrea S. Role of free radicals and poly(ADP-ribose)polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr. Med. Chem. (2008) 15 477-487."}, {"Citation": "Maggio D.M., Singh A., Iorgulescu J.B. et al. Identifying the long-term role of inducible nitric oxide synthase after contusive spinal cord injury using a transgenic mouse model. Int. J. Mol. Sci. (2017) 18 245."}, {"Citation": "Korhonen R., Lahti A., Kankaanranta H., Moilanen E. Nitric oxide production and signaling in inflammation. Curr. Drug Targets Inflamm. Allergy. (2005) 4 471-479."}, {"Citation": "Sharma J., Al-Omran A., Parvathy S. Role of nitric oxide in inflammatory diseases. Inflammopharmacology (2007) 15 252-259."}, {"Citation": "Amin A.R., Attur M.G., Thakker G.D. et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl Acad. Sci. USA. (1996) 93 14014-14019."}, {"Citation": "Zhang Y.-H., Chen H., Chen Y. et al. Activated microglia contribute to neuronal apoptosis in Toxoplasmic encephalitis. Parasit. Vectors. (2014) 7 372."}, {"Citation": "Sonmez E., Kabatas S., Ozen O. et al. Minocycline treatment inhibits lipid peroxidation, preserves spinal cord ultrastructure, and improves functional outcome after traumatic spinal cord injury in the rat. Spine. (2013) 38 1253-1259."}, {"Citation": "Niwa Y., Sakane T., Miyachi Y. Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates-in comparison with that of colchicine and various scavengers. Biochem. Pharmacol. (1984) 33 2355-2360."}, {"Citation": "Suda T., Suzuki Y., Matsui T. et al. Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. Br. J. Dermatol. (2005) 152 887-895."}, {"Citation": "Kraus R.L., Pasieczny R., Lariosa-Willingham K., Turner M.S., Jiang A., Trauger J.W. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem. (2005) 94 819-827."}, {"Citation": "R\u00e9us G.Z., Abelaira H.M., Maciel A.L. et al. Minocycline protects against oxidative damage and alters energy metabolism parameters in the brain of rats subjected to chronic mild stress. Metab. Brain Dis. (2015) 30 545-553."}, {"Citation": "Wang X., Ye L., Zhang K., Gao L., Xiao J., Zhang Y. Upregulation of microRNA-200a in bone marrow mesenchymal stem cells enhances the repair of spinal cord injury in rats by reducing oxidative stress and regulating Keap1/Nrf2 pathway. Artif. Organs (2020) 44 744-752."}, {"Citation": "Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. (2001) 2 502."}, {"Citation": "Golub L., Ramamurthy N., McNamara T. et al. Tetracyclines inhibit tissue collagenase activity. J. Periodontal Res. (1984) 19 651-655."}, {"Citation": "Paemen L., Martens E., Norga K. et al. T he gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem. Pharmacol. (1996) 52 105-111."}, {"Citation": "Ryan M.E., Usman A., Ramamurthy N., Golub L.M., Greenwald R.A. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr. Med. Chem. (2001) 8 305-316."}, {"Citation": "Power C., Henry S., Del Bigio M.R. et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann. Neurol. (2003) 53 731-742."}, {"Citation": "Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain (2002) 125 1297-308."}, {"Citation": "Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. (2004) 22 929-979."}, {"Citation": "Fuchs A.C., Granowitz E.V., Shapiro L. et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J. Clin. Immunol. (1996) 16 291-303."}, {"Citation": "Balasingam V., Yong V.W. Attenuation of astroglial reactivity by interleukin-10. J. Neurosci. (1996) 16 2945-2955."}, {"Citation": "Fiorentino D.F., Zlotnik A., Vieira P. et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. (1991) 146 3444-3451."}, {"Citation": "Ochoa-Aguilar A., Ventura-Martinez R., Sotomayor-Sobrino M.A., Gomez C., Morales-Espinoza M.R. Review of antibiotic and non-antibiotic properties of beta-lactam molecules. Antinflamm. Antiallergy Agents Med. Chem. (2016) 15 3-14."}, {"Citation": "Rothstein J.D., Patel S., Regan M.R. et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 433 73-7."}, {"Citation": "Yimer E.M., Hishe H.Z., Tuem K.B. Repurposing of the \u03b2-lactam antibiotic, ceftriaxone for neurological disorders: a review. Front. Neurosci. (2019) 13.236"}, {"Citation": "Fitzpatrick M.A., Suda K.J., Safdar N. et al. Unique risks and clinical outcomes associated with extended-spectrum beta-lactamase enterobacteriaceae in veterans with spinal cord injury or disorder: a case-case-control study. Infect. Control Hosp. Epidemiol. (2016) 37 768-776."}, {"Citation": "Tajkey J., Biglari A., Habibi Asl B., Ramazani A., Mazloomzadeh S. Comparative study on the effects of ceftriaxone and monocytes on recovery after spinal cord injury in rat. Adv. Pharm. Bull. (2015) 5 189-194."}, {"Citation": "Woo S.Y., Kim J.H., Moon M.K. et al. Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson\u2019s disease therapy. J. Med. Chem. (2014) 57 1473-1487."}, {"Citation": "R\u0131\u0301os C., Nader-Kawachi J., Rodriguez-Pay\u00e1n A.J., Nava-Ruiz C. Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats. Brain Res. (2004) 999 212-215."}, {"Citation": "Chatterjie N., Stables J.P., Wang H., Alexander G.J. Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity. Neurochem. Res. (2004) 29 1481-1486."}, {"Citation": "Rios C., Orozco-Suarez S., Salgado-Ceballos H. et al. Anti-apoptotic effects of dapsone after spinal cord injury in rats. Neurochem Res. (2015) 40 1243-1251."}, {"Citation": "Wozel G., Blasum C. Dapsone in dermatology and beyond. Arch. Dermatol. Res. (2014) 306 103-124."}, {"Citation": "Ren Y., Young W. Managing inflammation after spinal cord injury through manipulation of macrophage function. Neural. Plast. (2013) 2013 1-9."}, {"Citation": "Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. (2005) 5 953."}, {"Citation": "Chen H., Hsu P.-W., Tzaan W.-C., Lee A. Effects of the combined administration of vitamins C and E on the oxidative stress status and programmed cell death pathways after experimental spinal cord injury. Spinal Cord (2014) 52 24."}, {"Citation": "Oyinbo C.A. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol. Exp. (Wars). (2011) 71 281-299."}, {"Citation": "Putatunda R., Bethea J.R., Hu W.-H. Potential immunotherapies for traumatic brain and spinal cord injury. Chin. J. Traumatol. (2018) 21 125-136."}, {"Citation": "Zhang B., Bailey W.M., Kopper T.J., Orr M.B., Feola D.J., Gensel J.C. Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury. J. Neuroinflammat. (2015) 12 218."}, {"Citation": "Chen W., Lu N., Ding Y., Wang Y., Chan L.T., Wang X. et al. Rapamycin-Resistant mTOR activity is required for sensory axon regeneration induced by a conditioning lesion. eNeuro. (2016) 3."}, {"Citation": "Cordaro M., Paterniti I., Siracusa R., Impellizzeri D., Esposito E., Cuzzocrea S. KU0063794, a dual mTORC1 and mTORC2 inhibitor, reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. Mol. Neurobiol. (2017) 54 2415-2427."}, {"Citation": "Wang Z.Y., Liu W.G., Muharram A., Wu Z.Y., Lin J.H. Neuroprotective effects of autophagy induced by rapamycin in rat acute spinal cord injury model. NeuroImmunoModulation (2014) 21 257-67."}, {"Citation": "Saganova K., Orendacova J., Sulla I. Jr, Filipcik P., Cizkova D., Vanicky I. Effects of long-term FK506 administration on functional and histopathological outcome after spinal cord injury in adult rat. Cell. Mol. Neurobiol. (2009) 29 1045-1051."}, {"Citation": "Chen D., Zeng W., Fu Y., Gao M., Lv G. Bone marrow mesenchymal stem cells combined with minocycline improve spinal cord injury in a rat model. Int. J. Clin. Exp. Pathol. (2015) 8 11957-11969."}, {"Citation": "Papa S., Caron I., Erba E., Panini N., De Paola M., Mariani A. et al. Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury. Biomaterials (2016) 75 13-24."}, {"Citation": "Aras M., Altas M., Motor S., Dokuyucu R., Yilmaz A., Ozgiray E. et al. Protective effects of minocycline on experimental spinal cord injury in rats. Injury (2015) 46 1471-1474."}, {"Citation": "Pinkernelle J., Fansa H., Ebmeyer U., Keilhoff G. Prolonged minocycline treatment impairs motor neuronal survival and glial function in organotypic rat spinal cord cultures. PLoS One (2013) 8 e73422."}, {"Citation": "Sonmez E., Kabatas S., Ozen O., Karabay G., Turkoglu S., Ogus E. et al. Minocycline treatment inhibits lipid peroxidation, preserves spinal cord ultrastructure, and improves functional outcome after traumatic spinal cord injury in the rat. Spine. (2013) 38 1253-1259."}, {"Citation": "Lee J.H., Tigchelaar S., Liu J., Stammers A.M., Streijger F., Tetzlaff W. et al. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury. Exp. Neurol. (2010) 225 219-230."}, {"Citation": "Cho D.C., Cheong J.H., Yang M.S., Hwang S.J., Kim J.M., Kim C.H. The effect of minocycline on motor neuron recovery and neuropathic pain in a rat model of spinal cord injury. J. Korean Neurosurg. Soc. (2011) 49 83-91."}, {"Citation": "Marchand F., Tsantoulas C., Singh D., Grist J., Clark A.K., Bradbury E.J. et al. Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Europ. J. Pain (London, England). (2009) 13 673-681."}, {"Citation": "Pinzon A., Marcillo A., Quintana A., Stamler S., Bunge M.B., Bramlett H.M. et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res. (2008) 1243 146-151."}, {"Citation": "Yune T.Y., Lee J.Y., Jung G.Y., Kim S.J., Jiang M.H., Kim Y.C. et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci. (2007) 27 7751-7761."}, {"Citation": "Festoff B.W., Ameenuddin S., Arnold P.M., Wong A., Santacruz K.S., Citron B.A. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J. Neurochem. (2006) 97 1314-1326."}, {"Citation": "Stirling D.P., Khodarahmi K., Liu J., McPhail L.T., McBride C.B., Steeves J.D. et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. (2004) 24 2182-2190."}, {"Citation": "Lee S.M., Yune T.Y., Kim S.J., Park D.W., Lee Y.K., Kim Y.C. et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J. Neurotrauma (2003) 20 1017-1027."}, {"Citation": "Wells J.E., Hurlbert R.J., Fehlings M.G., Yong V.W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain J. Neurol. (2003) 126 1628-1637."}, {"Citation": "Garrido-Mesa N., Zarzuelo A., Galvez J. Minocycline: far beyond an antibiotic. Br. J. Pharmacol. (2013) 169 337-352."}, {"Citation": "Carnini A., Casha S., Yong V.W., Hurlbert R.J., Braun J.E. Reduction of PrP(C) in human cerebrospinal fluid after spinal cord injury. Prion. (2010) 4 80-86."}], "ReferenceList": [], "Title": "References"}], "History": [{"Year": "2020", "Month": "8", "Day": "6"}, {"Year": "2020", "Month": "2", "Day": "13"}, {"Year": "2020", "Month": "9", "Day": "8"}, {"Year": "2021", "Month": "1", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "19", "Hour": "12", "Minute": "19"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33464681", "10.1111/fcp.12605"]}}], "PubmedBookArticle": []}